The European Commission granted conditional marketing authorization for Libtayo (cemiplimab) for treating adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
With the books closed on another ASCO meeting, it’s clear to see that checkpoint inhibitors keep showing a promise.
Cancer drug study patients tend to be younger than most people with the disease in the general population.
Five-Year Survival Observed In Longest Follow-Up Of Advanced Melanoma Patients Treated With Opdivo-Yervoy Combination
Bristol-Myers Squibb Company announced updated results from studies evaluating Opdivo (nivolumab) and Yervoy (ipilimumab), alone or in combination, in patients with advanced or metastatic melanoma.
There was a flurry of activity during the first few days of the American Society of Clinical Oncology, with multiple presentations made showing the benefits of various oncology treatments.
The IQVIA Institute for Human Data Science is releasing the 2019 “Global Oncology Trends” report simultaneously with the American Society of Clinical Oncology (ASCO) Meeting.
At the American Society of Clinical Oncology 2019 Genitourinary Cancers Symposium (ASCO GU), companies have showcased more clinical data in presentations for prostate cancer treatment.
SCOUT and Rare Expertise Form Joint Venture to Help Identify and Treat People With Rare Diseases More Quickly and Accurately
SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activating people with rare disorders.
Astellas Pharma announced that the company is wrapping up its research operations with Santa Monica, Calif.-based Agenus.
In the eyes of investors, Bristol-Myers Squibb has not really recovered from bad news in August 2016 of its clinical trial of Opdivo (nivolumab) as monotherapy in non-small cell lung cancer. Although the company had quite a bit of good news at the June 2017 ASCO meeting, investors still seem leery.